• Lobbying Report: January 1 - March 31, 2024 (Action Fund) Federal (under tobacco issue code) Legislation: H.R. 4368/S. 2131- FY 24 Agriculture, Rural Developmental and Food and Drug Administration and Related Agencies Appropriations Bill FY 25 Agriculture, Rural Development, and Food and Drug Administration, and Related Agencies Appropriations Bill FY 25 Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill H.R. 5894/S. 2624 - FY 24 Labor, Health and Human Services, and Education, and Related Agencies Appropriations Bill H.R. 485 - Protecting Health Care for All Patients Act of 2023 H.R. 4366 - Consolidated Appropriations Act, 2024 H.R. 2882 - Further Consolidated Appropriations Act, 2024 S. 3653 - Resources to Prevent Youth Vaping Act Issues FDA proposed rule on menthol cigarettes. FDA proposed rule on flavored cigars Prevention and Public Health Fund FDA nicotine standard Tobacco Cessation FDA implementation of and enforcement of premarket review CDC Reform Tobacco User Fees FDA oversight of premium cigars Tobacco marketing/social media Online sales of tobacco products Nicotine pouches FDA oversight of heated tobacco products Medicaid coverage of tobacco cessation Agencies Visited: Centers for Disease Control and Prevention US House of Representatives US Senate Food and Drug Administration OMB GHAI Overdose Initiative (under healthcare issue code): Legislation: H.R. 3074/S. 971 - Due Process Continuity of Care Act S. 1165/H.R.2400- Reentry Act H.R. 1359/S.644 Modernizing Opioid Treatment Access Act Issues: Reforming Medicare Definition of incarcerated individuals Medicare coverage for seniors with substance use disorder Medicaid reform in jails/prisons Methadone access Agencies Visited: US Senate Centers for Disease Control and Prevention US House of Representatives ONDCP SAMHSA DEA CDC
• Lobbying Report: January 1 - March 31, 2024 (Action Fund) GHAI Overdose Initiative (under healthcare issue code): Legislation: H.R. 3074/S. 971 - Due Process Continuity of Care Act S. 1165/H.R.2400- Reentry Act H.R. 1359/S.644 Modernizing Opioid Treatment Access Act Issues: Reforming Medicare Definition of incarcerated individuals Medicare coverage for seniors with substance use disorder Medicaid reform in jails/prisons Methadone access Agencies Visited: US Senate Centers for Disease Control and Prevention US House of Representatives ONDCP SAMHSA DEA CDC

Duration: January 1, 2022 to present

General Issues: Tobacco, Health Issues

Spending: about $3,060,000 (But it's complicated. Here's why.)

It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.

Agencies lobbied since 2022: U.S. Senate, House of Representatives, Centers For Disease Control & Prevention (CDC), Office of Management & Budget (OMB), Food & Drug Administration (FDA), Drug Enforcement Administration (DEA), Substance Abuse & Mental Health Services Administration (SAMHSA), Office of Natl Drug Control Policy (NDCP), Health & Human Services - Dept of (HHS)

Affiliated organizations: Campaign for Tobacco Freee Kids